Daewoong “Ending the strain debate… alleging trade secrets and dismissing strain theft”
Maditox “Daewoong acquired negative strain… Proved by genetic analysis”
Conflict between the two companies when Daewoong Pharmaceutical, which has a botulinum toxin formulation,’Nabota’, and Medytox, which possesses’Meditoxin’, released the final ruling of the US International Trade Commission (ITC) on a lawsuit infringing trade secrets over the source of the strain. This is the appearance of re-ignition.
Daewoong claims that the debate has ended by proving that there is no trade secret of the strain, while Medytox argues that Daewoong’s fraudulent acquisition of the Medytox strain has become clear, and the two sides argue against each other over a single verdict. Is spreading.
Earlier, the ITC said in a full sentence on the morning of the 14th, “Meditox has not proved that the strain or its genetic makeup has a trade secret qualification, and there is no evidence to support the claim that it has obtained the status of trade secret even after obtaining the strain.”
The ITC finally ruled on the 16th of last month (local time) that it would ban Nabota’s imports for 21 months. Although it was 10 years in the preliminary judgment, the preliminary judgment that the trade secret exists in the strain of Medytox was not acknowledged, so it was significantly reduced.
However, ITC admitted the preliminary judgment that Daewoong acquired the strain of Medytox. ITC said, “The Meditox strain did not meet the requirements as a trade secret that can be protected, but the genetic evidence proves that Daewoong brought the strain from Medytox, and Daewoong Pharmaceutical’s theory of independent development of the strain is unreliable.” “Daewoong The preliminary judgment that the Medytox strain was acquired by this inappropriate means is evidence.”
ITC said, “Because it was determined that the Medytox strain was not a trade secret, Medytox could not clarify that Daewoong had committed a fraudulent act of stealing trade secrets.”
In response, Daewoong Pharmaceutical said, “Meditox claims that Daewoong has stolen the strain based on the results of the SNP strain analysis, but ITC acknowledged that this analysis has limitations and there is no evidence of strain theft.” “Meditox strains are trade secrets. As it was finally judged as not, in the future, the US Federal Court of Appeals will prove that the ITC’s decision to infringe on process technology is a clear misjudgment.”
An official from Daewoong said, “Meditox sincerely apologizes to the people for their various irregularities and illegal activities, and fully fulfill the responsibility for it.”
On the other hand, Medytox insisted that Daewoong’s theft of the strain was proven by the ITC’s final decision.
Medytox said, “As the ITC admitted that Daewoong’s Medytox strain was stolen, they reaffirmed that Daewoong’s claim that they had found the strain in Korean soil was a lie.” “Even in a domestic lawsuit, the court and the prosecution made the same judgment as ITC. We are confident that we will do so, and accordingly, we will ask Daewoong to prohibit the use of the strain and manufacturing process and return the right, and we will also dispose of the products currently in circulation and proceed with a claim for compensation.”
A Meditox official said, “I do not agree with the Committee’s judgment that the strain of Meditox is not a trade secret, but Daewoong is not entitled to steal even if it is not a trade secret.” “Even though the crime was clearly revealed, it did not admit the fault, and Daewoong, who is deceived by the public with allegations, will be held accountable until the end.”
Copyright owner © Doctor Shinmun Unauthorized reproduction and redistribution prohibited